Tahla Munir (Talha Munir)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Topics

Chronic Lymphocytic Leukemia

Prognostic Factors

Top Venues

American journal of hematology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

British journal of haematology

Therapeutic advances in hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Morag Griffin, Richard Kelly, Isabelle Brindel, Lynda Maafa, Roochi Trikha, Petra Muus, Tahla Munir, Abraham Mullasseril Varghese, Lindsay Mitchell, Sateesh Nagumantry, Shreyans Gandhi, Alex Pike, Austin G Kulasekararaj, Regis Peffault de Latour
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. American journal of hematology 99 (5) (2024)
Morag Griffin, Richard Kelly, Isabelle Brindel, Lynda Maafa, Roochi Trikha, Petra Muus, Tahla Munir, Abraham Mullasseril Varghese, Lindsay Mitchell, Sateesh Nagumantry, Shreyans Gandhi, Alex Pike, Austin G Kulasekararaj, Regis Peffault de Latour
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. American journal of hematology 99 (5) (2024)
Morag Griffin, Richard Kelly, Isabelle Brindel, Lynda Maafa, Roochi Trikha, Petra Muus, Tahla Munir, Abraham Mullasseril Varghese, Lindsay Mitchell, Sateesh Nagumantry, Shreyans Gandhi, Alex Pike, Austin G Kulasekararaj, Regis Peffault de Latour
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. American journal of hematology 99 (5) (2024)
Morag Griffin, Richard Kelly, Isabelle Brindel, Lynda Maafa, Roochi Trikha, Petra Muus, Tahla Munir, Abraham Mullasseril Varghese, Lindsay Mitchell, Sateesh Nagumantry, Shreyans Gandhi, Alex Pike, Austin G Kulasekararaj, Regis Peffault de Latour
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. American journal of hematology (2024)
Morag Griffin, Richard Kelly, Isabelle Brindel, Lynda Maafa, Roochi Trikha, Petra Muus, Tahla Munir, Abraham Mullasseril Varghese, Lindsay Mitchell, Sateesh Nagumantry, Shreyans Gandhi, Alex Pike, Austin G Kulasekararaj, Regis Peffault de Latour
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. American journal of hematology 99 (5) (2024)
Rocio Figueroa-Mora, Alexandros Rampotas, Daniel Halperin, Tina Worth, Jennifer Vidler, Dario Melotti, Paul Ferguson, Nagah Elmusharaf, Gavin Preston, Michelle Furtado, Moez Dungarwalla, Satyen Gohill, Piers Patten, Ben Kennedy, Toby Andrew Eyre, Anna Schuh, Christopher P Fox, Tahla Munir, Nicolas Martinez-Calle
Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study. British journal of haematology (2023)
Michael L Wang, Wojciech Jurczak, Pier Luigi Luigi Zinzani, Toby Andrew Eyre, Chan Yoon Y Cheah, Chaitra S Ujjani, Youngil Koh, Koji Izutsu, James N Gerson, Ian W Flinn, Benoît Tessoulin, Alvaro J Alencar, Shuo Ma, David John Lewis, Ewa Lech-Maranda, Joanna M Rhodes, Krish Patel, Kami Maddocks, Nicole Lamanna, Yucai Wang, Constantine S Tam, Tahla Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Timothy S Fenske, John Francis Seymour, Andrew D Zelenetz, Binoj Nair, Donald E Tsai, Minna Balbas, Richard A Walgren, Paolo Abada, Chunxiao Wang, Junjie Zhao, Anthony R Mato, Nirav N Shah
Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Tahla Munir, Victoria Genovez, Victor Genestier, Kellie Ryan, Bengt Liljas, Priyanka Gaitonde
Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States. Expert review of pharmacoeconomics & outcomes research (2023)
Wojciech Jurczak, Nagah Elmusharaf, Christopher Paul Fox, William M Townsend, Amanda G Paulovich, Jeffrey R Whiteaker, Fanny Krantz, Chuan-Chuan Wun, Graeme Parr, Shringi Sharma, Veerendra Munugalavadla, Richa Manwani, Emma Dean, Tahla Munir
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia. Therapeutic advances in hematology 14 (2023)
Tahla Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Osterborg, Tadeusz Robak, Martin Simkovic, Don Stevens, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P Kater
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Tahla Munir, Jake Emmerson, Anna Hockaday, Jamie B Oughton, Dena R Howard, David Phillips, Jeff Neilson, Nicholas Pemberton, Shankara Paneesha, Ben Kennedy, Andy Rawstron, Peter Hillmen
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British journal of haematology 199 (5) (2022)
Fraser L Macrae, Barnaby Peacock-Young, Polly Bowman, Stephen R Baker, Sam Quested, Emma Linton, Peter Hillmen, Morag Griffin, Tahla Munir, Daniel Payne, Claire McKinley, Deborah Clarke, Darren J Newton, Anita Hill, Robert A S Ariëns
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. American journal of hematology 95 (8) (2020)
Tahla Munir, Jennifer R Brown, Susan M O'Brien, Jacqueline C Barrientos, Paul M Barr, Nishitha M Reddy, Steven Coutre, Constantine S Tam, Stephen P Mulligan, Ulrich Jaeger, Thomas J Kipps, Carol Moreno, Marco Montillo, Jan A Burger, John C Byrd, Peter Hillmen, Sandra Dai, Anita Szoke, James P Dean, Jennifer A Woyach
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American journal of hematology 94 (12) (2019)